High-risk human papillomaviruses (HPVs) constitutively activate ataxia telangiectasia mutated (ATM) and ataxia telangiectasia-and Rad3-related (ATR) DNA damage repair pathways for viral genome amplification. HPVs activate these pathways through the immune regulator STAT-5. For the ATR pathway, STAT-5 increases expression of the topoisomerase IIβ-binding protein 1 (TopBP1), a scaffold protein that binds ATR and recruits it to sites of DNA damage. TopBP1 also acts as a transcriptional regulator, and we investigated how this activity influenced the HPV life cycle. We determined that TopBP1 levels are increased in cervical intraepithelial neoplasias as well as cervical carcinomas, consistent with studies in HPV-positive cell lines. Suppression of TopBP1 by shRNAs impairs HPV genome amplification and activation of the ATR pathway but does not affect the total levels of ATR and CHK1. In contrast, knockdown reduces the expression of other DNA damage factors such as RAD51 and Mre11 but not BRCA2 or NBS1. Interestingly, TopBP1 positively regulates the expression of E2F1, a TopBP1-binding partner, and p73 in HPV-positive cells in contrast to its effects in other cell types. TopBP1 transcriptional activity is regulated by AKT, and treatment with AKT inhibitors suppresses expression of E2F1 and p73 without interfering with ATR signaling. Importantly, the levels of p73 are elevated in HPV-positive cells and its knockdown impairs HPV genome amplification. This demonstrates that p73, like p63 and p53, is an important regulator of the HPV life cycle that is controlled by the transcriptional activating properties of the multifunctional TopBP1 protein.
Introduction
Human papillomaviruses (HPVs) are small DNA viruses that are the causative agents of cervical and many oropharyngeal cancers [1] [2] [3] . The life cycle of HPV is dependent on the differentiation of the infected epithelial host cells, with productive replication restricted to highly differentiated suprabasal cells [4] . HPVs infect cells in the basal layer of stratified epithelia and establish persistent infections that maintain low copies of HPV episomes in basal cells. The activation of late gene expression and induction of productive replication of viral episomes, which is referred to as amplification, are restricted to differentiated suprabasal cells [5] . The HPV early proteins include E1 and E2, which are responsible for the initiation of HPV replication [6, 7] , whereas E4 and E5 are involved in the regulation of late gene expression [8, 9] . The E6 and E7 proteins act to immortalize infected cells and are necessary for HPV genome maintenance in undifferentiated cells as well as amplification upon differentiation [10] [11] [12] [13] . The L1 and L2 late proteins encode the viral capsid proteins [2, 14, 15] .
The differentiation-dependent amplification of viral genomes is regulated by cellular transcription factors that bind to the early promoter in the upstream regulatory region (URR) as well as the late promoter located in the middle of the E7 ORF [16] . YY-1, TBP, AP-1, Oct-1, and Sp1 have been shown to regulate HPV early promoters [17] [18] [19] [20] [21] , whereas C/EBPβ, LIP, and LAP act on HPV late promoters [22] . Recent studies have shown that both the Kruppel-like factor 4 (KLF4) and KLF13 can regulate HPV amplification, but by different mechanisms [23, 24] . KLF4 forms complexes with Blimp1 to activate HPV late transcription, while KLF13 regulates STAT-5 expression. STAT-5 promotes HPV genome amplification by activating ataxia telangiectasia mutated (ATM) as well as ataxia telangiectasia-and Rad3-related (ATR) DNA damage repair pathways [25, 26] . Inhibition of either ATM or ATR signaling by pharmacological inhibitors or knockdown with short hairpin RNAs (shRNAs) suppresses HPV genome maintenance [27] or amplification [26, 28] . The ATR pathway is important for homologous recombination repair in response to single-strand DNA breaks, while ATM acts to repair double-strand breaks. ATR is recruited to sites of single-strand breaks in complexes with the ATR-interacting protein (ATRIP), claspin, and the topoisomerase IIβ-binding protein 1 (TopBP1), which results in its phosphorylation [29] . TopBP1 facilitates the activation of ATR through direct binding; however, it can also associate with several transcription factors such as E2F1 to regulate gene expression [30] [31] [32] [33] . The role of TopBP1 in transcriptional activation is regulated by phosphorylation, and this distinguishes its transcriptional activities from its effects on ATR activation [34] . It is, however, unclear what role the transcriptional effects of TopBP1 have in the HPV life cycle and what the critical targets are.
Our studies show that TopBP1 expression is increased in cervical intraepithelial neoplasia and cervical squamous cell carcinoma as well as in HPV-positive cell lines in culture. Knockdown of TopBP1 with shRNAs blocks ATR and CHK1 activation but has no effect on the total levels of these two factors. In contrast, TopBP1 knockdown greatly reduces the levels of other DNA damage factors such as RAD51 and Mre11, with minimal effects on other factors such as BRCA2 and NBS1. Interestingly, the transcriptional analysis of TopBP1-regulated genes in HPV-positive cells identifies both p73 and E2F1 as positive targets. This contrasts with the studies using other cell types that indicate TopBP1 as a repressor of E2F1 expression [30, 31] . Importantly, TopBP1mediated increases in the levels of p73 are shown to be important for genome amplification. This analysis demonstrates that the ability of TopBP1 to regulate transcription of cellular genes plays a critical role in the HPV life cycle.
Results

TopBP1 levels are increased in HPV-positive cervical cancers
To investigate the activities of TopBP1 that are critical for the HPV life cycle it was first important to demonstrate that the increased levels of TopBP1 seen in HPV-positive cell lines in tissue culture are also observed in clinical samples of varying degrees of cervical diseases. For this analysis, real-time PCR (RT-PCR) analysis of TopBP1 mRNA levels was performed using 90 human cervical tissue samples, including 29 normal cervical tissues, 31 HPV16-positive cervical intraepithelial neoplasias (CIN 2-3), and 30 HPV16-positive cervical cancers. As shown in Fig. 1a , there is an increase in the expression of TopBP1 in CIN 2-3 lesions as compared to that in normal tissues, which is further enhanced upon progression to cervical cancer. Similar increases in TopBP1 levels are seen in cell lines that contain HPV16, HPV18, or HPV31 episomes (HFK-16, HFK-18, and HFK-31), which were generated by the transfection of normal keratinocytes. We next screened for the distribution of TopBP1 protein by immunohistochemistry in an additional panel of 30 human cervical tissue samples, including 10 normal, 10 HPV16-positive CIN 2-3, and 10 HPV16-positive cervical cancer tissues ( Fig. 1b) . In normal tissues, TopBP1 is mainly detected at low levels in the nuclei of basal layer cells, with a further decrease in differentiated spinous layer cells and granular layer cells. In high-grade squamous intraepithelial lesions, the level of TopBP1 proteins is seen increased over that seen in normal tissues and is detected in all layers. Upon calcium-induced differentiation of both HFK-31 and CIN612 cells, increased levels of TopBP1 are observed in comparison to human foreskin keratinocytes (HFKs) ( Fig. 2a ). These studies demonstrate that the levels of TopBP1 are increased in both low-grade HPV cervical lesions and cancers and tissue culture cell lines ( Fig. 2b ). We also generated keratinocyte cell lines following infection with retroviruses expressing either E6 or E7 and confirmed that the E7 protein, but not E6, is responsible for the increases in TopBP1 levels [26] ( Fig. 2c ).
TopBP1 regulates the expression of DNA damage factors and cell cycle factors
TopBP1 is a scaffold protein that forms complexes with ATR and ATRIP, which are recruited to sites of DNA breaks, resulting in phosphorylation of ATR [35] . Knockdown of TopBP1 in cells that stably maintain HPV31 episomes using two different sets of shRNAs blocks ATR signaling and HPV genome replication ( Fig. 2d-f ), which is consistent with previous observations using transient assays [26] . TopBP1 knockdown does not affect the differentiation process, as the expression of keratin-10, a marker of differentiation, is unchanged. We previously demonstrated that viral proteins induce breaks into both cellular and viral DNAs [36] . Consistent with the recruitment of TopBP1 to sites of DNA breaks, we observed using chromatin immunoprecipitation assays that it binds to multiple regions of HPV genomes in both undifferentiated and differentiated states ( Supplementary Fig. 1 ).
TopBP1 also has transcriptional regulatory functions that require complex formation with factors such as E2F1, p53, and Miz1 [30, 33, 37] , and we investigated how TopBP1 transcriptional activities affected the HPV life cycle. For this analysis, keratinocytes that stably maintain HPV31 episomes (HFK-31 and CIN612) were infected with lentiviruses expressing shRNAs against TopBP1, and stable cell lines were selected by resistance to a co-expressed puromycin gene. Stable knockdown of TopBP1 was found to block ATR activation by phosphorylation but did not alter the total levels of ATR, as determined by western analysis (Fig. 3a ). This suggests that the increased ATR levels in HPV-positive cells are not due to TopBP1 but other factors. Similarly, knockdown of TopBP1 had no effect on the levels of the downstream effector kinase, CHK1, but it did prevent its activation by phosphorylation. We next investigated if TopBP1 knockdown affected the levels of other members of DNA damage repair pathways. Interestingly, our studies show that TopBP1 knockdown substantially reduced the levels of RAD51, Mre11 and, to a lesser extent, BRCA1, with minimal effect on the levels of BRCA2 or NBS1 (Fig. 3b ). This indicates that TopBP1 can control the expression of a number of DNA damage factors that are critical for HPV genome amplification. We next examined if the mRNA levels of RAD51, one of the DNA damage factors we identified as regulated by TopBP1, exhibited similar correlations with TopBP1 levels in CIN and cervical cancer biopsy specimens. Thirty biopsy samples of varying degrees of cervical disease were examined by RT-PCR, and RAD51 expression was found to exhibit similar increases as seen with TopBP1 ( Fig. 3c ). Additionally, we screened the expression of RAD51 in HPV-positive cells and found that the levels of RAD51 are greatly increased in HFKs that stably maintain HPV genomes ( Fig. 2a ). The E7 protein is responsible for the increase of RAD51 levels (Fig. 2b ). This indicates that in addition to regulating ATR activation TopBP1 also contributes to regulating the expression of a subset of DNA damage repair factors.
TopBP1 has been reported to bind to the E2F1 transcription factor and repress its ability to activate downstream genes [30] . We therefore investigated how TopBP1 affected E2F1 activities in HPV-positive cells. Our data show that the levels of E2F1 are increased in HPV-positive cells of three different high-risk types (HPV16, -18, and -31) as compared to normal keratinocytes ( Fig. 4a ). Similarly, we observed a substantial increase in E2F1 levels in HFKs that express HPV E7 ( Fig. 4b ). E6 was also found to modestly increase the levels of E2F1, and this is due to TopBP1-independent effects. Upon epithelial differentiation, the levels of E2F1 expression are higher in HPVpositive cells than in HFKs (Fig. 4c ). Importantly, TopBP1 knockdown with shRNAs significantly reduces E2F1 levels ( Fig. 4d ) but does not completely abrogate these levels. This residual level is likely due to the ability of E6 to activate E2F1 independent of TopBP1. RT-PCR analysis shows that the effect of TopBP1 on E2F1 is mediated at the level of transcription as mRNA levels are reduced upon shRNA knockdown and mimics the effects seen at the protein level ( Fig. 4e ). This indicates that the increased expression of E2F1 in HPV-positive cells is largely dependent upon enhanced levels of TopBP1 though other mechanisms may also contribute. One downstream transcriptional target of E2F1 is p73, and we investigated if its levels were altered due to TopBP1 knockdown in HPV-positive cells. Our studies show the levels of p73 are increased in HPVpositive cells in comparison to normal keratinocytes ( Fig. 4a ) and this is abrogated upon TopBP1 knockdown with shRNAs ( Fig. 4d, e ). RAD51 has also been suggested to be a downstream target of E2F1 [38, 39] , and the reductions we observe in TopBP1 knockdowns are likely the result of decreased E2F1 levels. RAD51 has been shown to be recruited to viral genomes and is a critical regulator of viral amplification [36, 40] . These studies indicate that in HPV-positive cells, TopBP1 positively increases E2F1 levels, which is in contrast to its effects reported in other cell types. Furthermore, TopBP1 does not act as a repressor of E2F1 action on downstream genes in HPV-positive cells but rather contributes to their activation.
To test whether the inhibition of HPV genome amplification upon TopBP1 knockdown is due to cell cycle arrest, we examined the effect of TopBP1 knockdown on cellcycle distribution of control and knockdown cells by flow cytometry analysis after propidium iodide (PI) staining. The scramble and TopBP1 knockdown CIN612 cells were fixed and permeabilized by 70% ethanol, stained with PI and analyzed by flow cytometry. Both knockdown and control cell populations exhibited similar cell-cycle distributions, with about 50% of cells in G1, 20% in G2, and 30% in S phase ( Fig. 4f ). In addition, we examined the growth rates of the stable scramble and TopBP1 knockdown cells and found them to be comparable ( Fig. 4g ). We conclude that the inhibition of amplification by TopBP1 following knockdown is not due to cell cycle arrest in G1.
AKT regulates the transcription functions of TopBP1
The ability of TopBP1 to regulate transcription is dependent upon its phosphorylation, which is controlled, in large part, by AKT kinase [34] . Phosphorylation of TopBP1 by AKT is necessary for TopBP1 repression of E2F1 activation but does not inhibit its binding to ATR. We first investigated whether AKT was activated in HPV-positive cells by western analysis using three HPV-positive cell lines that stably maintain viral episomes (HFK-16, -18, and -31) together with HFKs. All the three HPV-positive lines exhibited high levels of activation of AKT in comparison to normal keratinocytes, while the total levels of AKT were similar ( Fig. 5a ). To determine which viral proteins were responsible for increased levels of p-AKT, we infected HFKs with retroviruses expressing either E6 or E7 alone as F well as a combination of both the genes. In HFKs that express either E6 or E7 from retroviral vectors, the levels of phosphorylated AKT were increased ( Fig. 5b ). To investigate how AKT influenced TopBP1 phosphorylation, we first examined E7-alone expressing cells as these are the primary factor responsible for increased levels of TopBP1. Upon differentiation, E7-expressing cells maintained high levels of phosphorylated AKT, phosphorylated TopBP1, p73, and E2F1. To test whether AKT activation affects TopBP1-dependent E2F1 and p73 expression, E7expressing cells were treated with MK2206 ( Fig. 5c ) that blocks AKT phosphorylation but does not alter the total levels of AKT proteins. Our studies show that MK2206 treatment severely blocks phosphorylation of TopBP1 in E7-expressing cells and substantially reduces the levels of p73 and E2F1 but not activation of CHK1 phosphorylation. We next treated cells that stably maintain HPV episomes with MK2206 and observed decreases in the levels of p-AKT, p-TopBP1, p73, and E2F1, with no change in p-CHK1 activation (Fig. 5d ). To test whether AKT activation is required for HPV genome amplification, CIN612 cells were treated with two different AKT inhibitors MK2206 and LY294002. The DNA from these cells was examined by Southern blot analysis following calcium-induced differentiation; the results indicate that both inhibitors suppress HPV genome amplification ( Fig. 5e, f ). We conclude that inhibiting TopBP1 phosphorylation by AKT reduces the expression of E2F1 and p73 levels, which is consistent with our knockdown studies. This also demonstrates that the novel effects of TopBP1 on E2F1 activities are specific to HPV-positive cells. Interestingly, we also observed a reduction in TopBP1 levels in p73 knockdown cells, indicating that a feedback loop may exist between the two factors ( Supplementary Fig. 2 ).
E2F1 and p73 are downstream targets of TopBP1 transcriptional activities
The increased levels of p73 detected in HPV-positive cells is interesting since two other members of this family, p63 [41] and p53 [42] [43] [44] , have been shown to be critical for regulating the life cycle of high-risk HPVs. We next investigated whether p73 also provided an important function in the viral life cycle. First, the levels of p73 were examined in two additional cell lines that are positive for HPV16 or -18 (HFK-16 and -18 cells) to ensure increases are seen with other high-risk HPV types. We found all three high-risk types of HPV cells to express high levels of p73 ( Fig. 4a ). Figure 4b shows that E7 substantially increases the levels of E2F1 and p73 while E6 also can activate their expression but to a lesser degree than E7 does. Furthermore, following calcium-induced differentiation, the levels of p73 were also maintained at higher levels in HPV-positive cells as compared to HFKs (Fig. 4c ). To investigate if p73 has any effect on HPV life cycle, we screened for effects on viral replication. CIN612 cells were stably transduced with p73-specific shRNA lentiviruses, expanded and examined for amplification, following differentiation in high-calcium media. Figure 6a shows that two out of three p73 shRNAs examined are able to suppress p73 levels in comparison to cells transduced with lentiviruses expressing scrambled control shRNAs. We next examined the effect of p73 knockdown on amplification and found that this resulted in impaired genome amplification upon differentiation ( Fig.  6b ). We conclude that p73, like p63, has critical activities for regulating viral amplification in differentiating cells.
Additional downstream targets of TopBP1 transcriptional regulation
Our studies indicate that the transcriptional regulatory effects of TopBP1 are important for the HPV life cycle. We next sought to identify additional downstream targets of TopBP1 in HPV-positive cells by performing an unbiased global RNA-sequencing (RNA-seq) analysis with CIN612 cells in which TopBP1 was stably knocked down with shRNAs and compared the effects to cells treated with a scramble shRNA control. Both TopBP1 knockdown and scramble control cells were differentiated in high-calcium media for 72 h and RNAs isolated for RNA-seq analysis. To identify genes regulated by TopBP1, we set a threshold criteria of at least a 1.5-fold change and a minimum of 40-45 reads to eliminate genes that are expressed in low levels.
The genes that were found to be regulated by TopBP1 were categorized based on their functions and grouped using Metascape online tools. The top 20 pathways regulated by TopBP1 are shown in Fig. 7a , and the complete list of genes is included in Supplementary table 1. The largest group of genes include those regulating interferon signaling and the innate immune defense response. This indicates that TopBP1 may play a significant role in regulating the innate immune response (Fig. 7b ). We next sought to confirm the effect of TopBP1 on a small number of a specific interferon and innate immune regulatory genes by RT-PCR in TopBP1 knockdown cells. Previous studies have shown that interferon and interferon-stimulated gene expression are suppressed in HPV-positive cells [45] , and our studies indicate TopBP1 contributes to this regulation. Following TopBP1 knockdown, IFN-β, IFN-κ, CXCL2, CXCL10, IL-6, IL-8, and IL-18 are increased, as determined by RT-PCR ( Fig. 7c ). Similar effects of TopBP1 knockdown on these factors were observed following differentiation following suspension in methylcellulose ( Supplementary Fig. 3 ). We conclude that in addition to its positive effects on the activation of E2F1 and p73, TopBP1 also acts as a negative regulator of interferons, chemokines and some interleukins in HPV-positive cells.
Discussion
TopBP1 is a multifunctional protein that is critical for the activation of the ATR DNA damage repair pathway as well as for the regulation of transcription. Our studies show that TopBP1 levels are increased in low-grade HPV16-positive lesions and this is further enhanced upon progression to cancer. These increases are similar to those seen in our tissue culture models of precancerous lesions that are able to produce viruses upon differentiation. The increased levels of TopBP1 in HPV-positive cells are important for both the increased expression of a novel set of genes that are critical for the viral life cycle and the activation of ATR kinase. The ability to bind and activate ATR is separable from the role of TopBP1 in regulating transcription, and our studies show that each provides distinct critical functions for HPV pathogenesis. The levels of TopBP1 are similar among HFK-16, HFK-31, and CIN612 cells, which suggests that this increase does not depend on HPV type. Interestingly, the levels of TopBP1 were found to increase with progression from CIN to cancer. Many cancers contain integrated copies of HPV genomes, which often results in increased levels of E7 expression [46] , and this increase likely contributes to the higher levels of TopBP1. What role, if any, increased levels of TopBP1 might play in progression is still unclear.
The increased levels of TopBP1 in HPV-positive cells have no effect on the levels of ATR, but are necessary for the enhanced expression of other members of the DNA damage repair pathway including RAD51 and Mre11, with little to no effects on NBS1 or BRCA2. Interestingly, RAD51 and Mre11 are primarily associated with the double-strand DNA break repair ATM pathway and less so with the ATR pathway [47, 48] , which TopBP1 activates through direct binding to ATR [35] . TopBP1 acts to [30, 33, 37] . Binding of TopBP1 to E2F1 normally represses its transcriptional activating ability [30] , but in HPV-positive cells, we see the opposite effect. Interestingly, our studies indicate that TopBP1 also regulates the expression of E2F1 itself as knockdown inhibits its transcription. While stable knockdowns of TopBP1 in many cell types have been difficult to generate as most undergo apoptosis, the isolation of stable HPV-positive cells infected with lentiviruses expressing shRNAs against TopBP1 is readily achievable. In our TopBP1 knockdown cells, E2F1 expression is reduced in a process controlled by E7. This indicates that changes in the cellular environment induced by E7 action alter the requirements for TopBP1 functions so that cells no longer undergo cell death through apoptosis. Importantly, our studies show that in HPVpositive cells TopBP1 is a positive regulator of E2F1 expression.
In addition to activating the expression of E2F1 itself, high levels of TopBP1 also activate the expression of downstream targets such as p73 and RAD51 in HPVpositive cells. TopBP1 has also been shown to bind to the HPV E2 protein, which can modulate the levels of viral replication [49] ; however, the novel properties of TopBP1 observed in our studies cannot be explained by its binding to E2, as we observed similar effects on E2F1 and p73 in cells expressing E7 alone. This indicates that factors other than E2 are responsible for the positive effects of TopBP1 on transcription, but whether this is due to a novel binding partner or an upstream regulatory factor is unclear. While expression of p73 and RAD51 is regulated by E2F1, it is not clear whether Mre11 is similarly controlled but possible. High-level expression of E2F1 has been shown to be sufficient to activate DNA damage repair pathways, and this may in part be mediated by regulating the transcription of these factors. The question arises as to how TopBP1 can act as a repressor of E2F1 functions in HEK 293 and human fibroblasts but as an activator in HPV-positive cells. TopBP1 associates with E2F1 in large complexes together with other factors, and we believe additional regulators may be recruited to this complex in HPV-positive cells or, alternatively, the repressive complexes are prevented from forming.
The ability of TopBP1 to activate ATR can be distinguished from its role in regulating gene expression through phosphorylation by AKT kinase [34] . Phosphorylation of TopBP1 by AKT induces its oligomerization, resulting in its ability to associate with a series of transcription factors while blocking binding to ATR [31, 34] . Since both activation of ATR and increased expression of TopBP1-regulated genes are observed in our studies, a mixed population of phosphorylated and unphosphorylated forms must exist in HPV-positive cells. AKT is responsible for TopBP1 phosphorylation, and our data show that both E6 and E7 can increase p-AKT levels in stable cell lines. A previous study from the Vande Pol group showed that upon serum starvation followed by stimulation, a transient decrease in p-AKT levels is observed in cells that expressed HPV 16E7 as compared to normal immortal keratinocytes (NIKs). This transient decrease is in contrast to our findings using steady-state analysis. In addition, while both E6 and E7 are able to activate the AKT pathway, our studies indicate that only E7 activates TopBP1. This could be due to our previous observation that E7, but not E6, acts to activate the innate immune regulator STAT-5, which in turn directly regulates high levels of transcription of TopBP1 [26] . It is also possible that additional regulatory factors upstream of STAT-5 contribute to the increased levels of TopBP1 in E7 cells. In cells that express only E7, inhibition of TopBP1 phosphorylation decreases E2F1 and p73 expression. In contrast, in cells that express both E6 and E7, including those that harbor complete viral genomes, inhibition of TopBP1 phosphorylation substantially reduces, but does not completely abrogate, E2F1 and p73 transcription. We believe this indicates that while TopBP1 is a major positive regulator of E2F1 in HPV-positive cells, additional TopBP1-independent mechanisms exist that are likely regulated by E6.
One target of E2F1 that is increased in HPV-positive cells is p73, and by its knockdown we show that it is critical for the HPV life cycle. The other members of this family, p53 [42] and p63 [41] , also play critical roles in its life cycle. p53 levels are decreased in HPV-positive cells through the action of E6/E6AP, while p63 levels are Fig. 4 TopBP1 activates the expression of E2F1 and p73 in HPVpositive cells. a Western blot analysis of E2F1, p73 and GAPDH levels in HFK, HFK-16, HFK-18, and HFK-31 cells grown in monolayer cultures. b Western blot analysis of E2F1, p73 and GAPDH levels in HFK cells stably infected with LXSN vector control or retroviruses expressing HPV31E6, HPV31E7, and HPV31E6E7. c Western blot analysis of E2F1, p73, and GAPDH levels in HFK-, HFK-31-, and HPV31-positive CIN612 cells differentiated in highcalcium media for the indicated times (hrs). d Western blot analysis of E2F1, p73, p53, p63, and GAPDH levels in CIN612 cells stably infected with lentiviruses expressing shRNAs against TopBP1 following differentiation in high-calcium media for the indicated times (hrs). e RT-PCR analysis of TopBP1, E2F1, and p73 levels in CIN612 cells with TopBP1 knockdown in high-calcium media for the indicated times (hrs). GAPDH was used as internal control and for normalization of the data. Data = mean ± standard error. p value < 0.05. The experiments were repeated using two sets of TopBP1 shRNAs and only one was shown as a representative. f The cell-cycle distribution of the scramble CIN612 cells and the CIN612 cells with two different TopBP1 knockdowns was measured by flow cytometry following propidium iodide staining. g Comparison of the cell growth rates of CIN612 cells expressing scramble control or two different TopBP1 knockdowns. All results are representative of observations from two to three independent experiments increased through the suppression of miR-203 [50] , which normally inhibits p63 translation. Furthermore, p63 functions by activating the expression of KLF4 [23] in suprabasal layers to control the expression of genes regulating the cell cycle and differentiation. The specific downstream targets of p73 that are important for regulating the HPV life cycle are still unclear and are subject to future analysis. Multiple isoforms of p73 exist in cells, including full-length activator forms and N-terminal truncated forms ΔNp73, which are generated by alternative promoter usage. The activator TAp73 has been reported to increase expression of p53-responsive genes, while ΔNp73 acts as a repressor and both are likely important for HPV pathogenesis [51] [52] [53] . Interestingly, p73 proteins have been described as primarily expressed in brain and play roles in neuronal development as well as differentiation [54] . Furthermore, high levels of p73 proteins have been reported in HPV-positive oropharyngeal cancers [55] as well as in cells that contain the cutaneous HPV 38 [56] . The HPV 38 E6 and E7 proteins act to increase levels of p73, and this is important for repression of Toll-like receptor 9, which functions to restore UV-activated cell cycle checkpoint arrest [57] .
Our RNA-seq analysis identified a broad spectrum of genes whose expression is altered by TopBP1 in HPV-positive cells. In addition to activating expression of E2F1, p73, RAD51 and Mre11, our studies show that TopBP1 can also act as a repressor of one type of interferon specific to keratinocytes, IFN-κ, as well as cytokines IL-6 and IL-8. These genes have not been characterized as E2F1-regulated genes, and the mechanism by which TopBP1 acts to repress expression remains unclear, but IFN-κ suppression has been shown to be important for HPV replication [58] . Overall, our studies show that transcriptional regulatory activities of TopBP1 are critical for HPV life cycle. d Western blot analysis of p-AKT, AKT, p-TopBP1, TopBP1, E2F1, p73, p-CHK1, CHK1, and GAPDH protein levels in HPV31 cells upon differentiation in high-calcium media for 72 h in the presence of the AKT inhibitor MK2206. e Southern blot analysis of HPV31 episomes in CIN612 cells with MK2206 treatment following differentiation in high-calcium media for the indicated times (hrs). f Southern blot analysis of HPV31 episomes in CIN612 cells treated with LY294002 following differentiation in high-calcium media for the indicated times (hrs). All results are representative of observations from three independent experiments cell cultures require a coculture with mitomycin-treated NIH 3T3 J2 fibroblasts in E media. To induce differentiation, HPV-positive cells were cultured in keratinocyte basal medium without supplements and containing 1.5 mM CaCl 2 for up to 96 h as described [60] .
Clinical samples
The human cervical biopsy tissue samples assayed in this study were collected from Women's Hospital, Zhejiang University School of Medicine, China. The samples were obtained with written informed consent. All samples were immediately snap frozen in liquid nitrogen and stored at −80°C until use. The sample usage was approved by the Women's Hospital Research Ethical Committee of Zhejiang University.
Immunohistochemistry
The expression of TopBP1 protein was detected in 90 human cervical tissue samples using anti-TopBP1 antibody (Abcam). Tissue sections (4 μm) were obtained from formalin-fixed paraffin-embedded blocks and immunohistochemistry staining was performed using the Envision method [61] . In brief, nuclear staining within the squamous epithelium was assessed. Immunohistochemistry scoring analyses of TopBP1 expression were evaluated by Image pro-plus 6.0 (Media Cybernetics, Bethesda, MD, USA).
Antibodies and western blot analysis
The antibodies from this study were as follows: anti-keratin-10, anti-loricrin, anti-TopBP1, and anti-GAPDH (Santa Cruz, Santa Cruz, CA, USA); anti-E2F1, anti-p63, anti-ATR, anti-p-ATR, anti-CHK1, anti-p-CHK1, anti-CHK2, anti-p-CHK2, anti-RAD51, anti-Mre11, anti-NBS1, anti-BRCA1, and anti-BRCA2 (Cell Signaling, Danvers, MA); anti-p73 (Abcam, Cambridge, MA); anti-p53 (Millipore, Burlington, MA, USA); and anti-p-TopBP1 (Abgent, San Diego, CA, USA). AKT inhibitors MK2206 (2 μM) and LY294002 (25 μM) were purchased from SelleckChem (Houston, TX, USA). Cell lysates were processed and assayed by western blot analysis as previously described [60] . Briefly, J2 feeders were firstly removed by Versene (phosphate-buffered saline containing 0.5 mM ethylenediaminetetraacetic acid) treatment and keratinocytes were collected and lysed in radioimmunoprecipitation assay lysis buffer on ice for 30 min. The samples were then electrophoresed on sodium dodecyl sulphate-page gels and transferred to polyvinylidene difluoride membranes. At last the membranes were developed using ECL prime or ECL reagents (Amersham, Pittsburgh, PA, USA) and chemiluminescence signals were detected using Eastman Kodak Xray films.
Total RNA isolation and quantitative real-time PCR Total RNA was extracted using Trizol reagent (Invitrogen) or RNeasy mini kit (Qiagen) according to the manufacturer's instructions. Tissue cDNA was generated using the PrimeScript RT reagent Kit (TaKaRa) and quantitative real-time PCR (qPCR) was performed using SYBR Premix Ex Taq (TaKaRa). The cDNA products from cell culture were transcribed using an iScript cDNA synthesis kit (Bio-Rad). The real-time PCR was performed using a Light-Cycler 480 with LightCycler 480 SYBR green I master mix (Roche, Indianapolis, IN, USA). The specific primers were designed as follows: TopBP1 (5′-ATTACTCCAGGCCA AAGGAAGCAC-3′ (forward); 5′-AGCAAGGCTGGCTT GAGGTTTG-3′ (reverse)); RAD51 (5′-GATGGAGCAG CGATGTTT-3′ (forward); 5′-GGTTTCCCCTCTTCCTT TC-3′ (reverse)); E2F1 (5′-ACGTGACGTGTCAG-GACCT-3′ (forward); 5′-GATCGGGCCTTGTTTGCTCT T-3′ (reverse)); p73 (5′-ACGCAGCGAAACCGGGGCCC G-3′ (forward); 5′-GCCGCGCGGCTGCTCATCTGG-3′ APOBEC3G  IL6  IL15  DOCK2  SOCS3  DAPK1  IRF7  PML  PML.1  TRIM5  GBP2  GBP6  PSMB8  MX2  XAF1  CXCL10  HERC5  OASL  USP18  KYNU  BIRC3  CXCL5  ISG20  NLRC5  HLA−F  IFI35  IL1B  PTAFR  POLR3G  POLR3G.1  TRIM21  TRIM38  EGR1  STAT2  HLA−A  ADAR  B2M  OAS3  STAT1  HLA−B  HLA−C  TRIM22  DDX58  OAS1  PLSCR1  BST2  CXCL8  SAMHD1  SP100  IFI44L  IFI27  ISG15  IFIT1  OAS2  DDX60 Samples #3 and #4 are replicates of CIN612 cells with TopBP1 knockdown. c RT-PCR analysis of IFN-β, IFN-κ, CXCL2, CXCL10, IL-6, IL-8, and IL-18 in undifferentiated CIN612 cells with TopBP1 knockdown. GAPDH was used as internal control and for normalization of the data. Data = mean ± standard error. p value < 0.05. All results are representative of observations from two or more independent experiments (reverse)); and GAPDH (5′-GAGGACAGAGACCC AGCTGCC-3′ (forward); 5′-TGGAATTTGCCATGGGT G-3′ (reverse)). The results were normalized to those for GAPDH, and the data shown are representative of observations from three independent experiments. Significance was determined using Student's t test, and a p value of <0.05 was considered significant.
Southern blot analysis
Total DNA was extracted according to the standard protocol and the DNA samples were then assayed by Southern blot analysis as previously described [26] . Multiple nanodrop measurements were used to determine total DNA levels. Equal loading of gels was confirmed following electrophoresis by ethidium bromide staining.
Lentiviral virion production and transduction
MISSION shRNA lentiviral vectors (Sigma-Aldrich, St. Louis, MO, USA) expressing five TopBP1-specific shRNAs (constructs 1-5) were transfected into 293 T cells and lentiviral particles were prepared as previously described [25] . CIN612 cells were then incubated with concentrated TopBP1 shRNA or scramble shRNA lentiviral soup with 4 μg/ml hexadimethrine bromide (Polybrene; Sigma-Aldrich) in 5 ml total volume E media overnight at 37°C. The cells were washed the next day and maintained in fresh E media for an additional 48 h before further processing or analysis. Similar processes were applied to the preparation of p73 knockdown cells.
RNA-seq analysis
RNA-seq was performed at the University of Chicago using Illumina HiSeq 2500 NGS platform. Sequencing data were used as input for CRI Illumina RNA seq pipeline for reads mapping, post-alignment QC, and expression quantification, as well as DEG identification. The quality of raw sequencing reads was assessed using FastQC v0.11.5 [62] , and the postalignment QC was evaluated with RSeQC [63] and Picard tools v2.9.0 (http://broadinstitute.github.io/picard/). Reads were mapped to GENCODE human genome model (GRCh38) using STAR v2.5.3a [64] . Gene transcripts were assembled and quantified on their corresponding human genome using count-based method featureCounts [65] . Differentially expressed genes were identified with edgeR [66, 67] by comparing the duplicate samples in the treatment group with the duplicate scramble control samples. Finally, functional enrichment analysis was performed with Bioconductor package clusterProfiler [68] in R (R Core Team, 2014). The sequencingn be found at https://urldefense.proofpoint.com/v2/ url?u=https-3A__www.ncbi.nlm.nih.gov_geo_query_acc.cgi-3Facc-3DGSE122018&d=DwIEAg&c=Nd1gv_ZWYNIRy ZYZmXb18oVfc3lTqv2smA_esABG70U&r=bNhlmkh_CeP sRy5KUGx4MYh7P1dZ73zL--cpvyAFgUg&m=MT8zrpwQ XOeYMsXu4YAFpPk95kgW-3GTqfURJ5iP-wc&s=KBQY HBM6gSXL16CzyBkLR80zSu0hKOxv3Ws1p3U5PQs&e=.
